BIODELIVERY SCIENCES INTL (BDSI)
Common Stock
Overall BDSI gets a fundamental rating of 4 out of 10. We evaluated BDSI against 194 industry peers in the Pharmaceuticals industry. While BDSI seems to be doing ok healthwise, there are quite some concerns on its profitability. BDSI shows excellent growth, but is valued quite expensive already.
1. Profitability
1.1 Basic Checks
In the past year BDSI was profitable.
The reported net income has been mixed in the past 5 years: BDSI reported negative net income in multiple years.
In multiple years BDSI reported negative operating cash flow during the last 5 years.
1.2 Ratios
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 26.14% | ||
| ROE | 45.18% | ||
| ROIC | N/A |
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 22.27% | ||
| PM (TTM) | 50.91% | ||
| GM | N/A |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
2. Health
2.1 Basic Checks
Compared to 1 year ago, BDSI has less shares outstanding
Compared to 1 year ago, BDSI has an improved debt to assets ratio.
2.2 Solvency
An Altman-Z score of 2.65 indicates that BDSI is not a great score, but indicates only limited risk for bankruptcy at the moment.
BDSI has a Debt/Equity ratio of 0.29. This is a healthy value indicating a solid balance between debt and equity.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.29 | ||
| Debt/FCF | N/A | ||
| Altman-Z | 2.65 |
ROIC/WACCN/A
WACCN/A
2.3 Liquidity
BDSI has a Current Ratio of 2.45. This indicates that BDSI is financially healthy and has no problem in meeting its short term obligations.
A Quick Ratio of 2.17 indicates that BDSI has no problem at all paying its short term obligations.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 2.45 | ||
| Quick Ratio | 2.17 |
3. Growth
3.1 Past
BDSI shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 232.00%, which is quite impressive.
BDSI shows a strong growth in Earnings Per Share. Measured over the last years, the EPS has been growing by 71.95% yearly.
BDSI shows a small growth in Revenue. In the last year, the Revenue has grown by 6.54%.
The Revenue has been growing by 60.81% on average over the past years. This is a very strong growth!
EPS 1Y (TTM)232%
EPS 3Y37.54%
EPS 5Y71.95%
EPS Q2Q%520%
Revenue 1Y (TTM)6.54%
Revenue growth 3Y44.2%
Revenue growth 5Y60.81%
Sales Q2Q%2.33%
3.2 Future
The Earnings Per Share is expected to grow by 21.10% on average over the next years. This is a very strong growth
Based on estimates for the next years, BDSI will show a very strong growth in Revenue. The Revenue will grow by 23.45% on average per year.
EPS Next Y-57.48%
EPS Next 2Y-11.49%
EPS Next 3Y8.73%
EPS Next 5Y21.1%
Revenue Next Year22.27%
Revenue Next 2Y24.06%
Revenue Next 3Y23.25%
Revenue Next 5Y23.45%
3.3 Evolution
Although the future EPS growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.
The estimated forward Revenue growth is still strong, although it is decreasing when compared to the stronger growth in the past years.
4. Valuation
4.1 Price/Earnings Ratio
With a Price/Earnings ratio of 6.73, the valuation of BDSI can be described as very cheap.
The average S&P500 Price/Earnings ratio is at 29.70. BDSI is valued rather cheaply when compared to this.
BDSI is valuated correctly with a Price/Forward Earnings ratio of 15.84.
BDSI's Price/Forward Earnings ratio indicates a valuation a bit cheaper than the S&P500 average which is at 24.16.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 6.73 | ||
| Fwd PE | 15.84 |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | 11.15 |
4.3 Compensation for Growth
PEG (NY)N/A
PEG (5Y)0.09
EPS Next 2Y-11.49%
EPS Next 3Y8.73%
5. Dividend
5.1 Amount
No dividends for BDSI!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
BIODELIVERY SCIENCES INTL
NASDAQ:BDSI (3/22/2022, 8:00:02 PM)
After market: 5.6 +0.01 (+0.18%)5.59
0 (-0.09%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)
Earnings (Next)
Inst Owners
Inst Owner Change
Ins Owners
Ins Owner Change
Market Cap552.29M
Analysts
Price Target
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Dividend Growth(5Y)
DP
Div Incr Years
Div Non Decr Years
Ex-Date
Surprises & Revisions
EPS beat(2)
Avg EPS beat(2)
Min EPS beat(2)
Max EPS beat(2)
EPS beat(4)
Avg EPS beat(4)
Min EPS beat(4)
Max EPS beat(4)
EPS beat(8)
Avg EPS beat(8)
EPS beat(12)
Avg EPS beat(12)
EPS beat(16)
Avg EPS beat(16)
Revenue beat(2)
Avg Revenue beat(2)
Min Revenue beat(2)
Max Revenue beat(2)
Revenue beat(4)
Avg Revenue beat(4)
Min Revenue beat(4)
Max Revenue beat(4)
Revenue beat(8)
Avg Revenue beat(8)
Revenue beat(12)
Avg Revenue beat(12)
Revenue beat(16)
Avg Revenue beat(16)
PT rev (1m)
PT rev (3m)
EPS NQ rev (1m)
EPS NQ rev (3m)
EPS NY rev (1m)
EPS NY rev (3m)
Revenue NQ rev (1m)
Revenue NQ rev (3m)
Revenue NY rev (1m)
Revenue NY rev (3m)
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 6.73 | ||
| Fwd PE | 15.84 | ||
| P/S | |||
| P/FCF | |||
| P/OCF | |||
| P/B | |||
| P/tB | |||
| EV/EBITDA |
EPS(TTM)
EY
EPS(NY)
Fwd EY
FCF(TTM)
FCFY
OCF(TTM)
OCFY
SpS
BVpS
TBVpS
PEG (NY)N/A
PEG (5Y)0.09
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 26.14% | ||
| ROE | 45.18% | ||
| ROCE | |||
| ROIC | |||
| ROICexc | |||
| ROICexgc | |||
| OM | 22.27% | ||
| PM (TTM) | 50.91% | ||
| GM | N/A | ||
| FCFM |
ROA(3y)
ROA(5y)
ROE(3y)
ROE(5y)
ROIC(3y)
ROIC(5y)
ROICexc(3y)
ROICexc(5y)
ROICexgc(3y)
ROICexgc(5y)
ROCE(3y)
ROCE(5y)
ROICexcg growth 3Y
ROICexcg growth 5Y
ROICexc growth 3Y
ROICexc growth 5Y
OM growth 3Y
OM growth 5Y
PM growth 3Y
PM growth 5Y
GM growth 3Y
GM growth 5Y
F-Score
Asset Turnover0.51
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.29 | ||
| Debt/FCF | |||
| Debt/EBITDA | |||
| Cap/Depr | |||
| Cap/Sales | |||
| Interest Coverage | |||
| Cash Conversion | |||
| Profit Quality | |||
| Current Ratio | 2.45 | ||
| Quick Ratio | 2.17 | ||
| Altman-Z |
F-Score
WACC
ROIC/WACC
Cap/Depr(3y)
Cap/Depr(5y)
Cap/Sales(3y)
Cap/Sales(5y)
Profit Quality(3y)
Profit Quality(5y)
High Growth Momentum
Growth
EPS 1Y (TTM)232%
EPS 3Y37.54%
EPS 5Y
EPS Q2Q%
EPS Next Y-57.48%
EPS Next 2Y
EPS Next 3Y
EPS Next 5Y
Revenue 1Y (TTM)6.54%
Revenue growth 3Y44.2%
Revenue growth 5Y
Sales Q2Q%
Revenue Next Year
Revenue Next 2Y
Revenue Next 3Y
Revenue Next 5Y
EBIT growth 1Y
EBIT growth 3Y
EBIT growth 5Y
EBIT Next Year
EBIT Next 3Y
EBIT Next 5Y
FCF growth 1Y
FCF growth 3Y
FCF growth 5Y
OCF growth 1Y
OCF growth 3Y
OCF growth 5Y